Other languages Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
1,037 ^USD	+0.97%		+3.35%	+18.02%

Jun. 14	Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea	MT
Jun. 13	Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea	Jun. 14
Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing	Jun. 13
ETF de la semana: Una forma sencilla de reducir la volatilidad de la cartera	Jun. 13
Compañías que se deben tener muy en cuenta por técnico este miércoles en Wall Street	Jun. 12
Sanofi, Regeneron Secure US FDA Nod for Kevzara’s Use in Polyarticular Juvenile Idiopathic Arthritis	Jun. 11
Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Has Approves Kevzara®	Jun. 11
Regeneron Pharmaceuticals Insider Sold Shares Worth $798,821, According to a Recent SEC Filing	Jun. 10
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing	Jun. 05
ETF de la semana: Las energías limpias vuelven a despegar	Jun. 05
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier	Jun. 03
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials	Jun. 03
ETF de la semana: Las materias primas siguen teniendo potencial	May. 31
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	May. 31
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee	May. 31
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	May. 31
US-Prüfung für Sanofi-Arznei Dupixent um drei Monate verlängert	May. 31
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD	May. 31
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	May. 31
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,142,536, According to a Recent SEC Filing	May. 29
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	May. 23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Other languages

Filters